Alexandra M. Levine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra M. Levine has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Anil Tulpule
Division of Hematology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
2 shared publications Byron M. Espina
2 shared publications- Amrita Krishnan
City of Hope, Duarte, CA
1 shared publication Anil Tulpule
1 shared publication- Ariela Noy
Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication Bharat N. Nathwani
1 shared publication
Latest Publications
- 1 January 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (1) , 58-64
Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047
Purpose: Infusional chemotherapy is efficacious in patients with AIDS-related lymphoma, but it may be difficult to administer. We studied standard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt to provide a more practical approach to therapy while ascertaining rates of response, potential infectious complications, and prognostic role of biologic markers. Patients and Methods: We conducted a prospective, multi-institutional phase II trial, employing (day 1) pegylated liposomal doxorubicin 40 mg/m2, rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 (not > 2 mg), and prednisone 100 mg orally on days 1 through 5, with concomitant antiretroviral therapy. Results: In 40 evaluable patients, median CD4 cells was 114/μL (range, 5 to 1,026/μL), and median HIV-1 viral load (VL) was 25,000 copies/mL. High or intermediate/high age-adjusted International Prognostic Index was present in 28%. Overall response was 67.5%, with complete remission in 47.5% (95% CI, 31.5 to 63.9). Of 19 complete responders, 84% had extranodal disease, 47% had CD4 < 100/μL, and 47% had VL > 50,000 copies/mL; one relapsed. With 25.5-month median follow-up, 62% (95% CI, 44 to 75) of patients remain alive. Sixteen patients (40%) experienced 22 infections, with grade 4 in only two (5%). No patient died as a result of infection during treatment; one had opportunistic infection. Conclusion: Profound immunodeficiency and high HIV-1 viral load do not preclude attainment of complete response after DR-COP with highly active antiretroviral therapy. The regimen is tolerable, and use of rituximab was not associated with death as a result of infection during treatment. This approach may be useful in patients in whom the more intensive infusional regimens are impractical.
- 1 January 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (1) , 58-64
Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047
Purpose: Infusional chemotherapy is efficacious in patients with AIDS-related lymphoma, but it may be difficult to administer. We studied standard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt to provide a more practical approach to therapy while ascertaining rates of response, potential infectious complications, and prognostic role of biologic markers. Patients and Methods: We conducted a prospective, multi-institutional phase II trial, employing (day 1) pegylated liposomal doxorubicin 40 mg/m2, rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 (not > 2 mg), and prednisone 100 mg orally on days 1 through 5, with concomitant antiretroviral therapy. Results: In 40 evaluable patients, median CD4 cells was 114/μL (range, 5 to 1,026/μL), and median HIV-1 viral load (VL) was 25,000 copies/mL. High or intermediate/high age-adjusted International Prognostic Index was present in 28%. Overall response was 67.5%, with complete remission in 47.5% (95% CI, 31.5 to 63.9). Of 19 complete responders, 84% had extranodal disease, 47% had CD4 < 100/μL, and 47% had VL > 50,000 copies/mL; one relapsed. With 25.5-month median follow-up, 62% (95% CI, 44 to 75) of patients remain alive. Sixteen patients (40%) experienced 22 infections, with grade 4 in only two (5%). No patient died as a result of infection during treatment; one had opportunistic infection. Conclusion: Profound immunodeficiency and high HIV-1 viral load do not preclude attainment of complete response after DR-COP with highly active antiretroviral therapy. The regimen is tolerable, and use of rituximab was not associated with death as a result of infection during treatment. This approach may be useful in patients in whom the more intensive infusional regimens are impractical.
- 1 April 2012
- Published by Taylor & Francis in Hematology
- Vol. 17 (sup1) , s87-s89
Lymphomas and leukemias due to infectious organisms
World-wide, approximately 25% of all human malignancies are caused by infectious organisms, including approximately 10% of cancers occurring in resource rich areas of the world. While some of these disorders are more likely to be seen in patients with underlying immunodeficiency, this is not a requisite for development of malignancy, and most patients, in fact, are not immune-suppressed at the time of diagnosis. In considering hematologic malignancies, several organisms have been implicated in disease etiology. These organisms include Human Herpesvirus 8 (HHV8/KSHV), which is linked to primary effusion lymphoma and to multicentric Castleman s disease, as well as to development of Kaposi’s sarcoma; Epstein Barr Virus (EBV) which has been associated with Burkitt lymphoma and nasal T cell lymphoma, among others; Human T lymphotrophic virus type I (HTLV 1), which is associated with Adult T cell leukemia/lymphoma (ATLL) Hepatitis C virus, associated with splenic marginal and other lymphomas; and Helicobacter pylori, associated with gastric MALT lymphoma. The presentation will focus on the latter three disorders, describing pathogenesis of disease, clinical manifestations and therapeutic options.
- 1 April 2012
- Published by Taylor & Francis in Hematology
- Vol. 17 (sup1) , s87-s89
Lymphomas and leukemias due to infectious organisms
World-wide, approximately 25% of all human malignancies are caused by infectious organisms, including approximately 10% of cancers occurring in resource rich areas of the world. While some of these disorders are more likely to be seen in patients with underlying immunodeficiency, this is not a requisite for development of malignancy, and most patients, in fact, are not immune-suppressed at the time of diagnosis. In considering hematologic malignancies, several organisms have been implicated in disease etiology. These organisms include Human Herpesvirus 8 (HHV8/KSHV), which is linked to primary effusion lymphoma and to multicentric Castleman s disease, as well as to development of Kaposi’s sarcoma; Epstein Barr Virus (EBV) which has been associated with Burkitt lymphoma and nasal T cell lymphoma, among others; Human T lymphotrophic virus type I (HTLV 1), which is associated with Adult T cell leukemia/lymphoma (ATLL) Hepatitis C virus, associated with splenic marginal and other lymphomas; and Helicobacter pylori, associated with gastric MALT lymphoma. The presentation will focus on the latter three disorders, describing pathogenesis of disease, clinical manifestations and therapeutic options.
- 20 March 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (9) , 1514-1519
HIV As a Risk Factor for Lung Cancer in Women: Data From the Women's Interagency HIV Study
Purpose: Prior reports of an increased risk of lung cancer in HIV-infected individuals have not always included control groups, nor considered other risk factors such as tobacco exposure. We sought to determine the role of HIV infection and highly active antiretroviral therapy (HAART) on lung cancer incidence in 2,651 HIV-infected and 898 HIV-uninfected women from the Women's Interagency HIV Study (WIHS). Methods: A prospective study of the incidence rates of lung cancer was conducted, with cases identified through medical records, death certificates, and state cancer registries. Standardized incidence ratios (SIRs) were calculated to compare lung cancer incidence among HIV-infected and uninfected WIHS participants, with population-based expectations using the Surveillance, Epidemiology, and End Results registry. Behavioral characteristics in the WIHS were compared to US women by age and race adjusting the population-based data from the National Health and Nutritional Examination Survey (NHANES) III. Results: Incidence rates of lung cancer were similar among HIV-infected and uninfected WIHS women. Lung cancer SIRs were increased in both HIV-infected and -uninfected women compared with population expectations, but did not differ by HIV status. Among HIV-infected women, lung cancer incidence rates were similar in pre-HAART and HAART eras. All WIHS women with lung cancer were smokers; the risk of lung cancer increased with cumulative tobacco exposure. WIHS women were statistically more likely to smoke than US women studied in NHANES III. Conclusion: HIV infection is strongly associated with smoking behaviors that increase lung cancer risk. The role of HIV itself remains to be clarified.
- 20 March 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (9) , 1514-1519
HIV As a Risk Factor for Lung Cancer in Women: Data From the Women's Interagency HIV Study
Purpose: Prior reports of an increased risk of lung cancer in HIV-infected individuals have not always included control groups, nor considered other risk factors such as tobacco exposure. We sought to determine the role of HIV infection and highly active antiretroviral therapy (HAART) on lung cancer incidence in 2,651 HIV-infected and 898 HIV-uninfected women from the Women's Interagency HIV Study (WIHS). Methods: A prospective study of the incidence rates of lung cancer was conducted, with cases identified through medical records, death certificates, and state cancer registries. Standardized incidence ratios (SIRs) were calculated to compare lung cancer incidence among HIV-infected and uninfected WIHS participants, with population-based expectations using the Surveillance, Epidemiology, and End Results registry. Behavioral characteristics in the WIHS were compared to US women by age and race adjusting the population-based data from the National Health and Nutritional Examination Survey (NHANES) III. Results: Incidence rates of lung cancer were similar among HIV-infected and uninfected WIHS women. Lung cancer SIRs were increased in both HIV-infected and -uninfected women compared with population expectations, but did not differ by HIV status. Among HIV-infected women, lung cancer incidence rates were similar in pre-HAART and HAART eras. All WIHS women with lung cancer were smokers; the risk of lung cancer increased with cumulative tobacco exposure. WIHS women were statistically more likely to smoke than US women studied in NHANES III. Conclusion: HIV infection is strongly associated with smoking behaviors that increase lung cancer risk. The role of HIV itself remains to be clarified.
- 1 September 2008
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 20 (5) , 522-528
Management of AIDS-related lymphoma
With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved. Paradigms of therapy have changed. Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed. Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients. The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed. The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results. High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma. Highly active antiretroviral therapy should be used with chemotherapy. Addition of rituximab is associated with improved response rates, without an increase in infections. Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma. Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
- 1 September 2008
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 20 (5) , 522-528
Management of AIDS-related lymphoma
With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved. Paradigms of therapy have changed. Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed. Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients. The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed. The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results. High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma. Highly active antiretroviral therapy should be used with chemotherapy. Addition of rituximab is associated with improved response rates, without an increase in infections. Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma. Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
- Open Access
- 1 July 2008
- Published by SAGE Publications in Women's Health
- Vol. 4 (4) , 357-368
Malignancies in Women with HIV Infection
Women with HIV infection have an increased risk of developing certain malignancies. These malignancies are commonly human papillomavirus (HPV)-related, reflecting the high rate of coinfection with HPV in women with underlying HIV infection. These women also have a high incidence of premalignant HPV-related changes, such as high-grade squamous intraepithelial lesions as diagnosed on Pap smears and cervical intraepithelial neoplasia on cervical biopsy. Screening recommendations for HIV-infected women reflect the need for vigilance in detecting and treating these lesions early. In addition, recent interest has focused on the use of cervical cancer screening, employing HPV-testing techniques, and on HPV vaccination in younger women to prevent initial infection and the subsequent development of cervical and other HPV-related cancers. The incidence of other types of malignancies, such as Hodgkin's and non-Hodgkin's lymphoma, is also increased in HIV-infected individuals. When these lymphomas occur, they tend to be of advanced stage and high-grade histologies. The advent of highly active antiretroviral therapy has been associated with a marked decrease in the incidence of some of these cancers. The use of therapy has been associated with marked improvement in response rates and overall survival of affected patients.
- 1 July 2008
- Published by SAGE Publications in Women's Health
- Vol. 4 (4) , 357-368
Open AccessMalignancies in Women with HIV Infection
Women with HIV infection have an increased risk of developing certain malignancies. These malignancies are commonly human papillomavirus (HPV)-related, reflecting the high rate of coinfection with HPV in women with underlying HIV infection. These women also have a high incidence of premalignant HPV-related changes, such as high-grade squamous intraepithelial lesions as diagnosed on Pap smears and cervical intraepithelial neoplasia on cervical biopsy. Screening recommendations for HIV-infected women reflect the need for vigilance in detecting and treating these lesions early. In addition, recent interest has focused on the use of cervical cancer screening, employing HPV-testing techniques, and on HPV vaccination in younger women to prevent initial infection and the subsequent development of cervical and other HPV-related cancers. The incidence of other types of malignancies, such as Hodgkin's and non-Hodgkin's lymphoma, is also increased in HIV-infected individuals. When these lymphomas occur, they tend to be of advanced stage and high-grade histologies. The advent of highly active antiretroviral therapy has been associated with a marked decrease in the incidence of some of these cancers. The use of therapy has been associated with marked improvement in response rates and overall survival of affected patients.
- 1 August 2000
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (5) , 444-450
Chemotherapy Consisting of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With Granulocyte–Colony-Stimulating Factor in HIV-Infected Patients With Newly Diagnosed Hodgkin's Disease: A Prospective, Multi-institutional AIDS Clinical Trials Group Study (ACTG 149)
- 1 August 2000
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (5) , 444-450
Chemotherapy Consisting of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With Granulocyte–Colony-Stimulating Factor in HIV-Infected Patients With Newly Diagnosed Hodgkin's Disease: A Prospective, Multi-institutional AIDS Clinical Trials Group Study (ACTG 149)
- 1 May 1999
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 21 (1) , A38
PEG-L-ASPARAGINASE HAS ACTIVITY IN RELAPSED/REFRACTORY AIDS-RELATED LYMPHOMAS.
- 1 May 1999
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 21 (1) , A38
PEG-L-ASPARAGINASE HAS ACTIVITY IN RELAPSED/REFRACTORY AIDS-RELATED LYMPHOMAS.
- 1 December 1994
- Published by Wolters Kluwer Health in AIDS
- Vol. 8 (12) , 1695-1700
Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposiʼs sarcoma
To determine the toxicity and maximum tolerated dose of doxorubicin (adriamycin) in combination with fixed doses of bleomycin, vincristine (ABV) and zidovudine in patients with advanced AIDS-related Kaposi's sarcoma. Twenty-six HIV-seropositive men with Kaposi's sarcoma were treated daily with 100 mg zidovudine orally every 4 h, along with combination chemotherapy using bleomycin 10 U/m2 and vincristine 1.4 mg/m2 (maximum, 2 mg) given intravenously in 2-week cycles. In addition, three successive cohorts of eight patients received escalating doses of doxorubicin each beginning with no doxorubicin (level I), doses of 10 mg/m2 (level II), and 15 mg/m2 (level III). The major dose-limiting toxicity experienced with the combination therapy was severe neutropenia in eight patients, four of whom received level III doxorubicin (15 mg/m2). Therefore, 10 mg/m2 of doxorubicin in combination with zidovudine and BV chemotherapy was defined as the maximum tolerated dose. Other dose-limiting toxicities included neuropathy (n = 2), cutaneous toxicity associated with bleomycin (n = 1), and diarrhea (n = 1). Seventeen patients (71 %; 95% confidence interval, 46–85) experienced either partial (n = 13) or clinical complete remission (n = 4) to therapy after a median of five cycles (range, 2–9). The maximum tolerated dose of doxorubicin is 10 mg/m2 when given in combination with zidovudine and BV chemotherapy. Response rates observed with the combined antiretroviral and chemotherapy regimen are similar to those previously reported with ABV chemotherapy alone.
- 1 December 1994
- Published by Wolters Kluwer Health in AIDS
- Vol. 8 (12) , 1695-1700
Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposiʼs sarcoma
To determine the toxicity and maximum tolerated dose of doxorubicin (adriamycin) in combination with fixed doses of bleomycin, vincristine (ABV) and zidovudine in patients with advanced AIDS-related Kaposi's sarcoma. Twenty-six HIV-seropositive men with Kaposi's sarcoma were treated daily with 100 mg zidovudine orally every 4 h, along with combination chemotherapy using bleomycin 10 U/m2 and vincristine 1.4 mg/m2 (maximum, 2 mg) given intravenously in 2-week cycles. In addition, three successive cohorts of eight patients received escalating doses of doxorubicin each beginning with no doxorubicin (level I), doses of 10 mg/m2 (level II), and 15 mg/m2 (level III). The major dose-limiting toxicity experienced with the combination therapy was severe neutropenia in eight patients, four of whom received level III doxorubicin (15 mg/m2). Therefore, 10 mg/m2 of doxorubicin in combination with zidovudine and BV chemotherapy was defined as the maximum tolerated dose. Other dose-limiting toxicities included neuropathy (n = 2), cutaneous toxicity associated with bleomycin (n = 1), and diarrhea (n = 1). Seventeen patients (71 %; 95% confidence interval, 46–85) experienced either partial (n = 13) or clinical complete remission (n = 4) to therapy after a median of five cycles (range, 2–9). The maximum tolerated dose of doxorubicin is 10 mg/m2 when given in combination with zidovudine and BV chemotherapy. Response rates observed with the combined antiretroviral and chemotherapy regimen are similar to those previously reported with ABV chemotherapy alone.